分化簇155（CD155）是一种单次跨膜的细胞表面蛋白，在正常组织中表达量很少或不表达，但在包括胰腺癌、胆管癌、结直肠癌、非小细胞肺癌、膀胱癌、乳腺癌的多种恶性肿瘤中高表达，使其能够成为抗肿瘤药物的理想靶点。CD155作为细胞黏附分子参与肿瘤细胞的黏附、迁移和极化，还作为免疫调节分子与T细胞或NK细胞上的包括TIGIT、DNAM-1、CD96的共刺激或共抑制受体相互作用，发挥免疫调节作用，影响免疫微环境。目前靶向CD155及其受体的药物研发火热，其高亲和力受体TITIG有多种药物进入III期临床，直接靶向CD155及其受体DNAM-1和CD96的肿瘤治疗也逐渐增加。通过对靶向CD155及其受体的药物研究进展进行综述，以期为后续的药物研发提供依据。

Cluster of differentiation 155 (CD155) is a single-pass transmembrane cell surface protein with little or no expression in normal tissues, but in pancreatic cancer, cholangiocarcinoma, colorectal cancer, non-small cell lung cancer, bladder cancer and breast cancer. It is highly expressed in various malignant tumors of breast cancer, which makes it as an ideal target for anti-tumor drugs. As a cell adhesion molecule, CD155 participates in the adhesion, migration, and polarization of tumor cells. It also acts as an immunoregulatory molecule and interacts with costimulatory or costinhibitory receptors on T cells or NK cells, including TIGIT, DNAM-1, and CD96, which regulates and affects the immune microenvironment. At present, the research and development of drugs targeting CD155 and its receptors is hot, and its high-affinity receptor TITIG has a variety of drugs entering Phase III clinical trials, and tumor treatments that directly target CD155 and its receptors DNAM-1 and CD96 are also gradually increasing. This article reviews research progress of drugs targeting CD155 and its receptors, in order to provide a basis for subsequent drug development.

R966

湖北省科技支撑计划项目（2015BCA316）